Clinical trialsOfficial

Health Canada recalls Marcan cyclophosphamide injection lot over particulate matter

🇨🇦 Health Canada · Fri 30 Oct 2026

A single lot of Marcan Pharmaceuticals' Cyclophosphamide for Injection USP 1000 mg is subject to a Type I recall in Canada after particulate matter was found.

Health Canada has published a Type I recall of one lot of Cyclophosphamide for Injection USP, marketed by Marcan Pharmaceuticals Inc. The stated reason is the presence of particulate matter in the affected lot.

The recalled product is the 1000 mg/vial powder for solution, DIN 02560216, lot number 7Z10346A. No other lots or strengths are listed in the notice. The recall is filed under identification number RA-82896 and is classed as a product quality issue.

Distribution of the product was national, and the recall goes down to healthcare establishments rather than to individual patients. The notice is addressed to both the general public and the healthcare industry. Marcan Pharmaceuticals is based in Ottawa, Ontario.

Health Canada advises people with health concerns to consult their healthcare provider. It also tells them to contact the recalling firm with questions and to report any side effects or other safety complaints to the regulator. The page shows a last-updated date of 30 October 2026, but lists an original published date of 2 November 2026.

For context, Health Canada uses Type I for situations where there is a reasonable probability that using the product will cause serious adverse health consequences or death. The notice itself does not describe any adverse events or give further detail on the particulate matter.

What it means for your team

  • Hospital and healthcare-establishment pharmacies in Canada should check stock for lot 7Z10346A of Marcan's cyclophosphamide 1000 mg vials (DIN 02560216).
  • Quality teams should note that particulate contamination in a parenteral product has led to the highest recall classification, Type I.
  • The notice gives no root cause, no information on lot size and no reports of adverse events, so teams should contact Marcan Pharmaceuticals for further details.
  • Any suspected product-related adverse events should be reported to Health Canada.

Official source: Health Canada ↗

Article written by VigiEye from the official source (Health Canada). AI-assisted; check the source before acting.

More Clinical trials All →